Table 3.

Summary of HmAbs reactivity, neutralizing titer and heavy (H) and light (L) chain usage

HmAb	Groupa	Reactivity S1-IgG (12–672, 12–510, 261–672, 318–510)b	Binding regionc	Neutralizing titer 200TCID50 (μg/ml)d	H chaine	L chaine	H CDR3f	L CDR3f
4-E2	1A1	0.919, 1.518, 0.551, 1.839	318–510	0.781	VH1-2, D3-10, JH4B	A30, JK4	GPHSFGSGSYPFDY	QQYNSYPLT
4-G2	1A1	1.200, 1.662, 0.665, 1.811	318–510	0.781	VH1-2, D3-10, JH4B	A30, JK4	GPHSFGSGSYPFDY	QQYNSYPLT
6-C1	1A1	1.226, 1.586, 0.649, 2.405	318–510	0.781	VH1-2, D3-10, JH4B	A30, JK4	GPHSFGSGSYPFDY	QQYNSYPLT
3-A7	1B1	1.307, 1.523, 0.379, 1.964	318–510	0.195	VH1-18, D1-26, JH4B	A30, JK4	GRYLDY	LQYNSYPLT
5-A7	1B1	1.111, 1.449, 0.366, 1.997	318–510	0.781	VH1-18, D1-26, JH4B	A30, JK4	GRYLDY	LQYNSYPLT
5-D3	1B1	0.968, 1.316, 0.403, 2.020	318–510	0.195	VH1-18, D1-26, JH4B	A30, JK4	GRYLDY	LQYNSYPLT
5-D6	1B1	0.747, 1.313, 0.355, 2.117	318–510	0.195	VH1-18, D1-26, JH4B	A30, JK4	GRYLDY	LQYNSYPLT
6-B8	1B1	1.045, 1.704, 0.497, 2.133	318–510	0.781	VH1-18, D1-26, JH4B	A30, JK4	GRYLDY	LQYNSYPLT
4-A10	1B2	1.013, 1.524, 0.567, 1.792	318–510	3.125	VH1-2, D3-10, JH4B	A30, JK4	GPHTFGSGSYPFDY	QQYNSYPLT
6-C2	1B2	1.005, 1.603, 0.586, 1.849	318--510	0.781	VH1-2, D3-10, JH4B	A30, JK4	GPHTFGSGSYPFDY	QQYNSYPLT
3-F3	1B2	1.075, 1.349, 0.325, 1.887	318–510	0.781	VH1-2, D3-10, JH4B	A30, JK4	GPHTFGSGSYPFDY	QQYNSYPLT
5-A5	1B2	0.986, 1.187, 0.337, 2.310	318–510	0.195	VH1-2, D3-10, JH4B	A30, JK4	GPHTFGSGSYPFDY	QQYNSYPLT
6-B5	1B2	1.040, 1.324, 0.430, 2.087	318–510	3.125	VH1-2, D3-10, JH4B	A30, JK4	GPHTFGSGSYPFDY	QQYNSYPLT
5-E4	1B3	0.735, 1.199, 0.298, 2.275	318–510	12.5	VH1-2, N/A, JH4B	A30, JK5	GRYLDY	LQYNSYPIT
3-C7	1B4	1.092, 1.422, 0.357, 2.193	318–510	12.5	VH3-33, D2-2, JH4B	L5, JK4	DPLGYCSSTSCSYFDY	QQANNFPLT
6-B1	1B4	1.128, 1.166, 0.369, 2.093	318–510	3.125	VH3-33, D2-2, JH4B	L5, JK4	DPLGYCSSTSCSYFDY	QQANNFPLT
3-H12	1D	0.185, 0.318, 0.090, 1.304	318–510	3.125	VH4-59, D3-9, JH6B	A30, JK3	DYDILTGYSNYYGMDV	LQHNSYPFT
4-D4	2B1	0.258, 0.761, 0.103, 0.101	12–261	12.5	VH3-33, D4-17, JH4B	A1, JK2	GGDGERFDY	MQGTHWPPYVQ
1-B5	2B2	0.463, 1.292, 0.110, 0.191	12–261	0.195	VH3-33, N/A, JH5B	A30, JK4	GDFYWFDP	QQYNSYPLT

^aGroup designation based on fragment reactivity demonstrated previously and CDR3 sequence data.

^bOD values obtained for each mAb against indicated fragments during the original screen.

^cLikely binding region as determined previously by S1-IgG fragment reactivity.

^dConcentration of mAb that completely neutralizes 200TCID50 SARS-CoV (Urbani).

^eIg gene segment usage.

^fCDR3 sequences of each mAb.